Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes
Status:
Unknown status
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
Clinically, the ability to slow or prevent beta cell demise can prevent or improve the course
of type 1 diabetes. The immune-mediated destruction of beta cells that is an apparent major
pathological basis for the disease, has led to efforts to prevent or suppress this immune
assault. Here we propose to buttress the beta cell's capacity to withstand this assault by
improving the function of the endoplasmic reticulum stress resolving mechanisms within these
cells. The ability to do so could have a major impact on preventive and therapeutic
strategies for type 1 diabetes (and possibly other types of diabetes). The type of
endoplasmic reticulum stress relieving agent (TUDCA) proposed here could ultimately be
applied on an anticipatory basis to individuals at high risk for type 1 diabetes.